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Growing evidence has demonstrated that neurogenesis in the subventricular zone (SVZ) is significantly 
decreased in Parkinson’s disease (PD). Modulation of endogenous neurogenesis would have a significant 
impact on future therapeutic strategies for neurodegenerative diseases. In the present study, we investigated the 
augmentative effects of human mesenchymal stem cells (hMSCs) on neurogenesis in a PD model. Neurogenesis 
was assessed in vitro with 1-methyl-4-phenylpyridinium (MPP+) treatment using neural precursor cells (NPCs) 
isolated from the SVZ and in vivo with a BrdU-injected animal model of PD using 1-methyl-4-phenyl- 
1,2,3,6-tetrahydropyridine (MPTP). Immunochemical analyses were used to measure neurogenic activity. The 
number of BrdU-ir cells in the SVZ and the substantia nigra (SN) was significantly increased in the hMSC-
treated PD group compared with the MPTP-only-treated group. Double-stained cells for BrdU and tyrosine 
hydroxylase were notably observed in the SN of hMSC-treated PD animals, and they did not colocalize with 
the nuclear matrix; however, double-stained cells were not detected in the SN of the MPTP-induced PD animal 
model. Furthermore, hMSC administration increased the expression of the epidermal growth factor receptor 
(EGFR) in the SVZ of PD animals, and the coculture of hMSCs significantly increased the release of EGF in 
the medium of MPP+-treated NPCs. The present study demonstrated that hMSC administration significantly 
augmented neurogenesis in both the SVZ and SN of PD animal models, which led to increased differentiation 
of NPCs into dopaminergic neurons in the SN. Additionally, hMSC-induced modulation of EGF seems to be 
an underlying contributor to the enhancement of neurogenesis by hMSCs. The modulation of endogenous adult 
neurogenesis to repair the damaged PD brain using hMSCs would have a significant impact on future strategies 
for PD treatment.
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in the SVZ and hippocampus is significantly decreased in 
patients with PD and in animal models of PD (3,14) and 
that neurochemical deficits of dopamine, indirect effects 
of growth factor release, and α-synuclein accumulation in 
neural precursor cells (NPCs) of the SVZ by disease pro-
cess may influence neurogenic activity (5,8,33). In par-
ticular, the NPCs in the SVZ express dopamine receptors, 
and several animal data suggest that dopamine-enhancing 
drugs increase neurogenic activity through the epidermal 
growth factor receptor (EGFR) in conjunction with the 
release of EGF in the SVZ (14,24).
Mesenchymal stem cells (MSCs) are present in adult 
bone marrow and represent <0.01% of all nucleated 
bone marrow cells. MSCs are themselves capable of 
INTRODUCTION
Recent studies have demonstrated that the adult mam-
malian brain has the potential to generate new neurons and 
to incorporate them into brain areas affected by a disease 
process (12,22). Neurogenesis in the subventricular zone 
(SVZ) and the subgranular zone of the dentate gyrus may 
act as an endogenous repair mechanism (10); thus, modula-
tion of endogenous neurogenesis would have a significant 
impact on future therapeutic strategies for neurodegenera-
tive diseases such as Alzheimer’s disease and Parkinson’s 
disease (PD) (13). Several factors, including neurotransmit-
ters, growth factors, and disease states, have been suggested 
to play a role in the regulation of endogenous neurogenesis 
(1). Growing evidence has demonstrated that neurogenesis 
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multipotency, with differentiation under appropriate con-
ditions into chondrocytes, skeletal myocytes, and neurons. 
Moreover, MSCs secrete various cytotrophic factors that, in 
turn, exert neuroprotective effects (6). We previously dem-
onstrated that human MSCs (hMSCs) had neuroprotective 
properties in Parkinsonian disorders through a variety of 
mechanisms, such as antiapoptotic effects, modulation of 
polyubiquitinated proteins, and anti-inflammatory actions, 
in addition to possible transdifferentiation of hMSCs 
into dopaminergic neurons (16,26,27). Furthermore, this 
cytotrophic effect of MSCs on neurogenic modulation has 
been studied in animal models of stroke, demonstrating 
that MSCs promoted neurogenic activity in the SVZ and 
migration of NPCs into damaged lesions (21). Recently, 
Cova and colleagues (7) showed that intrastriatal implan-
tation of hMSCs enhanced neurogenesis in the SVZ and 
induced the migration of neuroblasts toward the lesioned 
striatum in a 6-hydroxydopamine-induced PD animal 
model, possibly mediated through sustained expression 
of brain-derived neurotrophic factor (BDNF). In the pres-
ent study, we investigated whether intravenous injection 
of hMSCs would modulate neurogenesis in the SVZ and 
thus enhance differentiation of NPCs into the dopaminer-
gic phenotype in the substantia nigra (SN) using a 1-meth-
yl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced 
animal model of PD.
MATERIALS AND METHODS
Animal Study
To create an MPTP-induced animal model of PD, 
C57BL/6 adult male mice aged 16 weeks (Samtako Bio 
Korea, Seoul, South Korea) were injected with MPTP 
(20 mg/kg IP, four times a day at 2-h intervals, each 
group, n = 5). Control mice (n = 5) were injected with 
saline alone using the same administration method. At 
3 days after MPTP injection, hMSCs were injected into 
the tail vain (1 × 106 cells/200 ml). At 4 days after MPTP 
injection, bromodeoxyuridine (BrdU; 50 mg/kg IP) was 
injected consecutively for 5 days. Histopathological ana-
lyses were compared among three groups of mice (control 
group, MPTP-only group, and hMSC treatment in MPTP 
group). The in vivo study design is illustrated in Figure 1. 
The animal work was approved by the institutional ani-
mal care and use committees of Yonsei University.
Isolation of hMSCs
Bone marrow aspirates (10 ml) were obtained from the 
iliac crests of human donors (n = 3, aged 25–40). The mono-
nuclear cell layer was isolated by Ficoll–Hypaque, washed 
in PBS, plated in 100-mm polystyrene plastic culture dishes, 
and cultivated in low-glucose Dulbecco’s modified Eagle’s 
medium (Gibco-BRL, Grand Island, NY) containing 10% 
fetal bovine serum (Hyclone, Irvine, CA) and 1% penicillin/
streptomycin (P/S, Sigma, St. Louis, MO) in a humidified 
incubator at 37°C under 5% CO2. Nonadherent cells were 
removed after 24 h. When these primary cultures reached 
80% confluence, the cells were harvested using 0.25% 
trypsin and subcultured. At passage 6, hMSCs were injected 
into the mice via the tail vain (1 × 106 cells/mouse). 
Tissue Preparation 
For immunohistochemistry, the mice were perfused with 
saline solution containing 0.5% sodium nitrate and heparin 
(10 U/ml) and fixed with 4% paraformaldehyde dissolved 
in 0.1 M phosphate buffer (PB, ~50 ml/mouse) at 8 (early 
time) and 30 days (late time) after MPTP injection. The 
brains were removed from the skulls, postfixed overnight in 
buffered 4% paraformaldehyde at 4°C, and stored in a 30% 
sucrose solution for 1–2 days at 4°C until they sank. They 
were then sectioned to obtain 30-µm coronal sections. The 
30-µm coronal sections were stored in tissue stock solution 
(30% glycerol, 30% ethylene glycol, 30% thrice-distilled 
water, 10% 0.2 M PB) at 4°C until required. 
Antibodies
Antibodies and dilutions used in this study were mouse 
anti-tyrosine hydroxylase (TH) (1:2,000 dilution for brain 
tissue; 1:7,500 dilution for cell culture; Pel-freez, AR), 
rabbit anti-TH (1:2,000 dilution for brain tissue; 1:7,500 
dilution for cell culture; Chemicon, Temecula, CA), 
mouse anti-nuclear matrix (NuMA, a nuclear marker) 
Figure 1. In vivo study design. At 3 days after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) injection, human mesenchymal 
stem cells (hMSCs) were injected into the tail vain (1 × 106 cells/mouse). At 4 days after MPTP injection, bromodeoxyuridine (BrdU; 
50 mg/kg IP) was injected consecutively for 5 days. The mice were perfused at 8 (early time) and 30 days (late time) after MPTP 
injection.
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(1:100 dilution; Calbiochem, San Diego, CA), rabbit anti-
Ki67 (1:500 dilution; Abcam, Cambridge, UK), mouse 
anti-BrdU (1:200 dilution; Roche, San Francisco, CA), 
rabbit anti-EGFR (1:100 dilution; Imgenex, San Diego, 
CA), and CD105, CD90, CD44, CD34, and CD45 (1:100 
dilution; Chemicon, Temecula, CA) for immunochemis-
try and immunofluorescence. The different primary anti-
bodies were codetected by immunofluorescence using 
goat anti-mouse IgG Alexa Fluor-488 (green) and goat 
anti-rabbit IgG Alexa Fluor-594 (red) (1:200; Molecular 
Probes, Eugene, OR).
Immunohistochemistry and Immunocytochemistry
The 30-µm coronal brain sections and cultured NPCs 
were washed twice in PBS and incubated in 0.2% Triton 
X-100 for 30 min at room temperature (RT). Then they 
were rinsed three times with 0.5% bovine serum albumin 
(BSA) in 1 × PBS for blocking. After blocking, they were 
incubated overnight at 4°C with primary antibody. The 
brain sections were then rinsed three times in 0.5% BSA in 
1 × PBS (10 min/rinse) and incubated with the appropriate 
biotinylated secondary antibody and avidin–biotin complex 
(Elite Kit; Vector Laboratories, Burlingame, CA) for 1 h at 
RT. Bound antibodies were visualized by incubating with 
0.05% diaminobenzidine–HCl (DAB) and 0.003% H2O2 
in 0.1 M PB. The brain sections and cultured NPCs were 
rinsed with 0.1 M PB for DAB inhibition. For BrdU immu-
nohistochemistry, the section tissues before blocking were 
incubated with 0.6% H2O2 in 1 × PBS for 10 min and rinsed 
three times in 1 × PBS. After rinsing, they were incubated 
with 50% formamide in 2 × SSC DW (standard saline cit-
rate distilled water) for 1–2 h at 65°C and rinsed three times 
in 2 × SSC DW. After rinsing, the brain sections were incu-
bated with 2 N HCl in DW for 30 min at 37°C and rinsed 
three times in 1 × PBS. They were then incubated in 0.2% 
Triton X-100 for 30 min at RT, and routine immunohis-
tochemical procedure was then followed. Immunostained 
cells were analyzed by brightfield microscopy.
Immunofluorescence Double Labeling
The 4-µm sections of embedded paraffin tissues were 
rinsed three times with 0.5% BSA in 1 × PBS for blocking. 
After blocking, they were incubated overnight at RT or 4°C 
with the primary antibodies TH+NuMA (to detect dopamin-
ergic neurons differentiated from hMSCs) and TH+Ki67 
(to detect dopaminergic neurons differentiated from pro-
liferating cells, i.e., NPCs). The brain sections were then 
rinsed three times in 0.5% BSA in 1 × PBS (10 min each 
rinse) and incubated with secondary antibody: goat anti-
mouse IgG (Alexa Fluor-488, green) and goat anti-rabbit 
IgG (Alexa Fluor-594, red) for 1 h at RT. Brain tissues 
were then washed and mounted using Prolong Antifade 
Kit (Molecular Probes). Stained tissues were viewed using 
an Olympus I X 71 confocal laser scanning microscope 
(Olympus, Tokyo, Japan). To analyze the localization of 
different antigens in double-stained samples, immunofluo-
rescence images were created from the same tissue section 
and merged using interactive software.
Cell Cultures of NPCs and SH-SY5Y
A parasagittal section was taken from the medial surface 
of each hemisphere of postnatal day 1 Sprague–Dawley 
rat (male and female, n = 28; Samtako Bio Korea, Seoul, 
South Korea), and a wedge of tissue was microdissected 
from the portion of the lateral ventricle that included the 
anterior part of the SVZ (23). The tissues were incubated 
in Ca2+-, Mg2+-free Hank’s balanced salt solution (CMF-
HBSS) for 10 min and 0.01% trypsin in CMF-HBSS for 
9 min at 37°C. Cultures were rinsed twice in Dulbecco's 
modified Eagle's medium supplemented with 10% fetal 
bovine serum, 6 mg/ml glucose, 204 µg/ml l-glutamine, 
and 100 U/ml P/S to inhibit trypsin, and they were then 
dissociated into single cells by trituration. The mono-
nuclear cell layer was plated in 100-mm polystyrene 
plas tic culture dishes and cultivated in Dulbecco’s modi-
fied Eagle’s medium (Gibco-BRL) containing 10% fetal 
bovine serum (Hyclone) and 1% penicillin/streptomycin 
(P/S, Sigma) in a humidified incubator at 37°C under 5% 
CO2. Nonadherent cells were removed after 24 h. When 
these primary cultures reached 20% confluence, the cells 
were harvested using 0.25% trypsin and subcultured. 
SH-SY5Y cells (neuroblastoma cell lines, ATCC, USA) 
were maintained in Dulbecco’s modified Eagle’s medium 
supplemented with 10% fetal bovine serum (FBS). Cells 
were cultured in 25 cm2 flasks and passaged by using 
trypsin–EDTA solution. Cells were subcultured into indi-
vidual a Transwell 1 day before the experiment.
For treatment, cultured NPCs at passage 3 were plated 
on 12-mm round Aclar plastic coverslips or 24-well culture 
plates at a density of 1.0 × 105 cells/coverslip/well. Cells 
were incubated in a humidified incubator at 37°C and 5% 
CO2 for 24 h. At 2 days, the cultures were pretreated with 
MPP+ (100 µM) for 24 h. After MPP+ was washed off, 
primary NPC cultures were then cocultured with 3 × 104 
hMSCs or 1 × 105 SH-SY5Y cells/well for 24 h using a 
Transwell. The cocultured cells were used for immuno-
chemistry, cell proliferation assay, and ELISA assay.
EGF ELISA and MTS Assay
The MPP+-stimulated NPCs were cocultured with 
vehicle or hMSCs using a Transwell, and the level of 
EGF was determined in the supernatant of MPP+-treated 
NPCs. The supernatant was stored in a fresh tube, and 
a sandwich ELISA was performed according to the 
manufacturer’s instructions (Alpco, Salem, NH). The 
MPP+-stimulated NPCs were cocultured with vehicle or 
hMSCs using a Transwell, and an MTS cell proliferation 
assay was performed. Each well of cocultured cells was 
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incubated in DMEM with 20% AQueous One solution 
regent at 37°C for 1 h, and the absorbance was recorded 
at 490 nm using a 96-well plate reader. The MTS assay 
was performed according to the manufacturer's instruc-
tions (Promega, Madison, WI).
Stereological Cell Counts
Unbiased stereological estimations of the total num-
ber of stained cells in the SN and SVZ were made using 
an optical fractionator as previously described, with 
some modifications (17). This sampling technique is not 
affected by tissue volume changes and does not require 
reference volume determinations (31). The sections used 
for counting covered the entire SN from the rostral tip 
of the pars compacta back to the caudal end of the pars 
reticulata and the lateral wall of the SVZ. This generally 
yielded eight to nine sections in a series. Sampling was 
performed using the Olympus CAST-Grid system (Olympus 
Denmark A/S, Albertslund, Denmark), using an Olympus 
BX51 microscope connected to the stage and feeding the 
computer with the distance information in the z-axis. The 
SN and SVZ were delineated at 1.25× objective. A counting 
frame (60%, 35,650 µm2) was randomly placed onto the first 
counting area and systematically moved through all count-
ing areas until the entire delineated area was sampled. Actual 
counting was performed using a 40× oil objective. Guard 
volumes (4 µm from the top and 4–6 µm from the bottom of 
the section) were excluded from both surfaces to avoid the 
problem of a lost cap, and only the profiles that came into 
focus within the counting volume (with a depth of 10 µm) 
were counted. The total number of stained cells was calcu-
lated according to the optical fractionator formula (30).
Statistical Analysis
Data are expressed as mean ± SE. Comparisons between 
groups were made using the Student’s t test (paired) or one-
way analysis of variance (ANOVA) followed by a Dunnett 
post hoc test. Values of p < 0.05 were considered statistically 
significant. Statistical analyses were performed using com-
mercially available software (SPSS version 10.0; SPSS, 
Inc., Chicago, IL).
RESULTS
Characterization of hMSCs
Fluorescence-activated cell sorting (FACS) analy-
sis demonstrated that hMSCs expressed CD29, CD44, 
CD73, and CD105, positive markers for hMSCs, and did 
not express CD14, CD34, CD45, and CD106, negative 
markers for hMSCs (Fig. 2A). Immunofluorescent label-
ing showed that hMSCs were positive for CD44, CD90, 
and CD105 and negative for CD34 and CD45 (Fig. 2B).
Effect of hMSCs on Loss of Dopaminergic Neurons  
in MPTP-Induced Animal Models
To determine the effects of hMSCs on the loss of dopa-
minergic neurons, brain tissue in the SN was immunostained 
Figure 2. Flow cytometric analysis (A) and immunofluorescent labeling of hMSCs (B). Scale bar: 100 µm.
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with TH, a marker for dopaminergic neurons. As expected, 
there was a marked increase in the loss of TH-ir in MPTP-
induced PD animal models; however, hMSC treatment 
markedly attenuated the loss of TH-ir cells in MPTP-
induced PD animal models (Fig. 3A). Stereological analy-
sis revealed that the number of TH-ir cells in the SN was 
significantly higher in the hMSC-treated group than in 
the MPTP-only-treated group (5,680 ± 105 vs. 2,990 ± 36, 
p < 0.05) (Fig. 3B and Table 1).
Effect of hMSCs on Neurogenesis in the SVZ  
of MPTP-Induced PD Animal Models
To determine the effects of hMSCs on regulation of NPC 
proliferation, brain tissue in the SVZ was immunostained 
Figure 3. Effect of hMSCs on survival of dopaminergic neurons in MPTP-induced Parkinson’s dis-
ease (PD) animal models. hMSC treatment markedly attenuated the loss of tyrosine hydroxylase 
(TH)-ir cells in MPTP-induced PD animals (A), and stereological analysis revealed that the number 
of TH-ir cells in the substantia nigra (SN) was significantly higher in the hMSC-treated group than 
in the MPTP-only-treated group (B) (n = 5; *p < 0.05). Scale bar: 100 µm.
Table 1. The Number of Cells in the Control and MSC-Treated Groups
Cell Types Areas Time (Days) Control MPTP MPTP + hMSCs p
TH SN 30 10,900 ± 89 2,990 ± 36a 5,680 ± 105b <0.05
BrdU SVZ  8 15,720 ± 519 10,480 ± 796 14,040 ± 925 NS
30 17,160 ± 668 8,560 ± 341a 14,640 ± 703b <0.01
SN  8 960 ± 69 1,100 ± 144 1,700 ± 22c <0.05
30 840 ± 183 580 ± 163 1,660 ± 177b,c <0.05
EGFR SVZ  8 4,240 ± 524 2,360 ± 222a 2,760 ± 317 <0.05
30 3,200 ± 105 1,200 ± 183a 2,400 ± 138b <0.01
MSCs, mesenchymal stem cells; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; TH, tyrosine hydroxylase; 
BrdU, bromodeoxyuridine; EGFR, epidermal growth factor receptor; SN, substantia nigra; SVZ, subventricular zone.
aComparison between control and MPTP.
bComparison between MPTP and MPTP + hMSCs.
cComparison between control and MPTP + hMSCs.
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with BrdU, a marker for cell proliferation. At 8 and 30 days 
after MPTP injection, the number of BrdU-ir cells in the 
SVZ was prominently decreased in MPTP-induced PD ani-
mals; however, hMSC treatment in MPTP-induced PD ani-
mals significantly attenuated the neuronal loss of BrdU-ir 
cells in the SVZ at both early and late times (Fig. 4A). 
Stereological analysis revealed that the number of BrdU-ir 
cells in the SVZ was significantly increased in the hMSCs-
treated group compared with the MPTP-only-treated group 
at late time (14,640 ± 703 vs. 8,560 ± 341, p < 0.01), whereas 
the difference in BrdU-ir cells between these groups was not 
significant at early time (Fig. 4B and Table 1). The number 
of NPCs in the SVZ did not differ significantly between the 
hMSCs-treated PD and control groups in both the early and 
late periods after BrdU injection.
Effect of hMSCs on Neurogenesis in the SN  
of MPTP-Induced PD Animal Models
BrdU-ir cells in the SN were more frequently 
observed in the hMSCs-treated group than in the MPTP-
only-treated or control groups in both the early and late 
periods after BrdU injection (Fig. 5A). Stereological 
analysis revealed that the number of BrdU-ir cells in the 
SN was significantly greater in the hMSCs-treated group 
compared with the MPTP-only-treated group in the late 
period of BrdU injection (1,660 ± 177 vs. 580 ± 163, 
p < 0.05) (Fig. 5B and Table 1). BrdU-ir cells in the 
early period of BrdU injection tended to be higher in 
the hMSCs-treated group than in the MPTP-only-treated 
group; however, this difference did not reach statistical 
difference (Table 1). 
Figure 4. Effect of hMSCs on neurogenesis in the subventricular zone (SVZ) of MPTP-induced PD 
animal models. hMSC treatment prominently increased the number of BrdU-ir cells in the SVZ of 
MPTP-treated PD animal models (A). Stereological analysis revealed that the number of BrdU-ir 
cells in the SVZ was significantly greater in the hMSCs-treated group compared with the MPTP-only-
treated group at 30 days after MPTP injection (B) (n = 5; *p < 0.05, **p < 0.01). Scale bar: 100 µm. 
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hMSCs Enhanced Differentiation of NPCs  
Into Dopaminergic Phenotype in the SN
To evaluate whether hMSCs would augment dopami-
nergic differentiation from NPCs, brain tissue in the SN 
areas was double immunostained with Ki67, a marker 
for cell proliferation, and TH, a marker for dopaminergic 
neurons, at 22 days after last BrdU injection. Ki67 and 
TH-ir cells were not detected in the SN of the MPTP-
induced PD animal model; however, double-stained cells 
were notably observed in the SN of hMSCs-treated PD 
animals (Fig. 6A). On stereological analysis, the number 
of cells double stained with Ki67 and TH in the SN was 
189 ± 52, which roughly corresponded to 10% of the total 
number of Ki67-ir cells at 22 days after last BrdU injec-
tion (Fig. 6B). Furthermore, these double-stained cells 
did not colocalize with NuMA (Fig. 6C), a marker for 
human-specific cells, which indicates that these cells did 
not originate from the hMSCs injected via the tail vein.
Modulatory Effect of hMSCs on Expression of EGFR  
in the SVZ
EGF is known to enhance proliferation of NPCs in the 
SVZ by binding to the EGFR that is present on activated 
B cells and rapidly dividing C cells (11). To evaluate the 
effects of hMSCs on the expression of EGFR, the area 
of the SVZ was immunostained with EGFR. The expres-
sion of EGFR was prominently decreased in the SVZ of 
MPTP-treated PD animals compared with controls; how-
ever, hMSC treatment notably increased the expression of 
EGFR in the SVZ of MPTP-treated PD animals (Fig. 7A). 
Figure 5. Effect of hMSCs on neurogenesis in the SN of MPTP-induced PD animal models. BrdU-ir 
cells in the SN (arrows) were more frequently observed in the hMSCs-treated group than in the 
MPTP-only-treated or control groups in both the early and late periods after BrdU injection (A). 
Stereological analysis revealed that the number of BrdU-ir cells in the SN was significantly greater in 
the hMSCs-treated group than in the MPTP-only-treated group in the late period of BrdU injection (B) 
(n = 5; *p < 0.05). Scale bar: 100 µm.
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Stereological analysis showed that the number of EGFR-ir 
cells in the SVZ was significantly lower in MTPT-treated 
PD animals compared with controls (the early period: 
4,240 ± 524 vs. 2,360 ± 222, p < 0.05; the late period: 3,200 ± 
105 vs. 1,200 ± 183, p < 0.01), whereas hMSC treat ment led 
to a significant increase in EGFR-ir cells of MPTP-treated 
PD animals the late period of BrdU injection (2,400 ± 138 
vs. 1,200 ± 183, p < 0.01) (Fig. 7B and Table 1).
Direct Effect of hMSCs on Survival of NPCs In Vitro
To investigate the effect of hMSCs on survival of NPCs 
obtained from the SVZ, the NPCs were cocultured with 
SH-SY5Y cells or hMSCs using a Transwell after MPP+ 
treatment and analyzed immunocytochemically in a 24-h 
incubation period. The MPP+ administration or coculture 
with SH-SY5Y cells induced marked loss of NPCs com-
pared with the controls, whereas coculture with hMSCs 
showed a significant reduction in the loss of NPCs com-
pared with MPP+ alone (Fig. 8A). Stereological and MTS 
analyses also showed that the survival of NPCs after MPP+ 
administration was significantly higher in the hMSCs 
treatment group than in the MPP+-only or SH-SY5Y 
cells treatment group (Fig. 8B, C). To evaluate the effect 
of hMSCs on the modulation of EGF, we determined 
the level of EGF in the medium of MPP+-treated NPCs. 
The level of EGF was significantly higher in the medium 
cotreated with hMSCs compared with the MPP+-only or 
SH-SY5Y cells-treated medium (Fig. 8D). 
DISCUSSION 
The present study demonstrated that hMSC adminis-
tration significantly augmented neurogenesis in both the 
SVZ and SN of PD animal models, which led to increased 
differentiation of NPCs into dopaminergic neurons in 
the SN. Furthermore, hMSCs-induced EGF modula-
tion appears to be one of underlying contributors to the 
enhancement of neurogenesis by hMSCs. Our data sug-
gest that the modulation of endogenous adult neurogen-
esis to repair the damaged PD brain using hMSCs would 
have a significant impact on future strategies for PD 
treatment.
Growing evidence has suggested that the neurogenic 
activity in the SVZ and dentate gyrus is significantly 
decreased in PD (3,14) and that dopaminergic modulation 
of the NPCs through a nigrostriatal pathway is an important 
contributor to the neurogenesis of PD (5). Additionally, 
the PD-related microenvironment of α-syncline is known 
Figure 6. Enhanced differentiation of NPCs into the dopaminergic phenotype in the SN by hMSCs. Brain tissue in the SN areas was 
double immunostained with Ki67 and TH at 22 days after last BrdU injection. Ki67 and TH-ir cells were not observed in the SN of 
MPTP-induced PD animal model; however, double-stained cells were notably observed in the SN of hMSCs-treated PD animals (A). 
On stereological analysis, the number of double-stained cells in the SN was 189 ± 52, which roughly corresponded to 10% of the total 
number of Ki67-ir cells (B). These double-stained cells did not colocalize with antinuclear matrix (NuMA), a marker for human-
specific cells (C). Arrows indicate double-stained cells with TH and Ki67.
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to decrease neurogenesis via disturbed notch-1 expres-
sion as well as increased induction of apoptosis in NPCs 
of the SVZ (8). Our study demonstrated that hMSC treat-
ment had augmentative effects on neurogenesis against 
MPTP-induced NPC loss in the SVZ, showing 13% and 
35% increases in the survival of BrdU-positive cells at 
early and late periods of BrdU injection, respectively. 
This result is well in accordance with previous studies 
that demonstrated the neurogenic effects of MSCs in ani-
mal models of PD and ischemic stroke. 
Several lines of evidence have suggested that endog-
enous dopaminergic neurogenesis occurs at a low level in 
the SN of healthy mice and increases after introduction of 
neurotoxin, although the results were not consistent due to 
Figure 7. Modulatory effect of hMSCs on expression of epidermal growth factor receptor (EGFR) in 
the SVZ. The expression of EGFR was prominently decreased in the SVZ of MPTP-treated PD ani-
mals compared with that of the controls; however, hMSC treatment notably increased the expression 
of EGFR in the SVZ of MPTP-treated PD animals (A). Stereological analysis showed that hMSC 
treatment led to a significant increase in EGFR-ir cells of MPTP-treated PD animals at 22 days after 
last BrdU injection, that is, day 30 (B) (n = 5; *p < 0.05, **p < 0.01). Scale bar: 100 µm.
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methodological differences among the studies (immuno-
histochemical staining, BrdU dose, or section thickness) 
(2,13). The present study demonstrated for the first time 
that hMSC administration significantly increased the 
number of BrdU-ir cells in the SN of MPTP-treated PD 
animal models. In particular, dopaminergic phenotypes 
incorporated with the Ki67 label were notably discovered 
in the SN of hMSCs-treated PD animals. Because MSCs 
can transdifferentiate into cells exhibiting dopaminergic 
phenotypes, we further determined the origin of these 
double-merged cells using NuMA staining, a marker 
for human-specific cells. These cells did not colocalize 
Figure 8. Direct effect of hMSCs on survival of neural progenitor cells (NPCs) in vitro. To investigate the effect of hMSCs on the sur-
vival of NPCs obtained from the SVZ, the NPCs were cocultured with hMSCs or SH-SY5Y cells using a Transwell after MPP+ treat-
ment. The MPP+ administration or coculture with SH-SY5Y cells induced marked loss of NPCs compared with the controls, whereas 
coculture with hMSCs resulted in a significant reduction in the loss of NPCs (A). Stereological and MTS analyses showed that the 
survival of NPCs after MPP+ administration was significantly higher in the hMSC treatment group than in the MPP+-only or SH-SY5Y 
cells treatment group (B and C). The level of EGF in the medium of NPCs cotreated with hMSCs was significantly higher compared 
with the change of MPP+-only treatment or coculture with SH-SY5Y cells (D). (n = 3; *p < 0.05, **p < 0.01). Scale bar: 100 µm.
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with NuMA, indicating that they did not originate from 
hMSCs injected via the tail vein; instead, they probably 
originated from NPCs. However, our data did not provide 
information on whether hMSC-induced cell prolifera-
tion in the SN may occur in situ from resident NPCs or 
progeny migrating from the SVZ. Nevertheless, our study 
indicates that along with the neuroprotective properties of 
hMSCs on dopaminergic neurons, enhancement of dopa-
minergic differentiation from the NPCs by hMSCs plays 
a role in the sparing effects of dopaminergic neurons in 
the SN of PD animals. 
The neurogenic activity of hMSCs in our PD models 
appeared to be mediated by complex mechanisms. First, 
our study demonstrated that hMSCs modulate the induc-
tion of EGF in NPCs of the SVZ. In this study, hMSC 
administration notably increased the expression of EGFR 
in the SVZ of MPTP-treated PD animals, and coculture 
of hMSCs significantly increased the release of EGF 
in the medium of MPP+-treated NPCs. Like other neu-
rotrophic factors, EGF is known to be an endogenous 
regulator of SVZ neurogenesis, thus leading to a sig-
nificant enhancement in proliferation and migration of 
NPCs in the SVZ (18,28), although the fate of the newly 
generated cells has been controversial. Additionally, 
hMSCs possess the ability for the induction of various 
neurotrophic factors, such as BDNF, nerve growth factor 
(NGF), insulin-like growth factor (IGF), and EGF (15). In 
an animal model of ische mic stroke, Wakabayashi et al. 
(30) demonstrated that hMSCs significantly induced the 
endogenous expression of EGF in the host cells. In this 
regard, hMSCs would enhance neurogenic activity in the 
SVZ of PD models via modulation of endogenous EGF 
expression. Second, hMSC administration in the present 
study attenuated dopa minergic neuronal death in the SN 
of MPTP-treated PD animals. Recent studies have dem-
onstrated that NPCs in the SVZ exhibited dopaminergic 
receptors and dopaminergic innervation that originated in 
the SN (14), suggesting the important role of dopamin-
ergic modulation in the neurogenic activity of the SVZ. 
Adding to the evidence that dopamine agonists augment 
neurogenesis in animal models of PD (14,32), O’Sullivan 
et al. (25) very recently demonstrated a positive impact of 
chronic levodopa use on the number of neural stem cells in 
the SVZ of patients with PD. Furthermore, a recent study 
showed that dopamine stimulated the release of EGF from 
cells in the SVZ and in turn acted on the EGFR to pro-
mote cell proliferation (24), suggesting a role of EGF as 
a key mediator of dopamine-induced neurogenesis in the 
SVZ. Therefore, increased survival of dopaminergic neu-
rons in the SN by hMSCs would enhance neurogenesis in 
the SVZ through activation of dopaminergic receptors or 
EGFR in the NPCs. Finally, our in vitro data showed that 
hMSC treatment increased survival of NPC MPP+-induced 
neuro toxicity. We previously demonstrated that hMSCs 
can restore the balance between neuronal survival and 
apoptosis through upregulation of cell survival signaling 
pathways and suppression of apoptotic cell death signal-
ing (26,27). Together, our data suggest that the neuropro-
tective properties of hMSCs on NPCs of the SVZ also 
seem to be involved in the modulation of neurogenesis. 
Regarding the functional impact of adult neurogenesis, 
several lines of evidence have suggested that adult neu-
rogenesis plays a regulatory role in olfaction, mood, and 
memory functions. In particular, Van Kampen and Eckman 
(29) reported that, in a PD animal model, an increase in 
neurogenesis following treatment with a dopaminergic 
drug restored the nigrostriatal dopaminergic projection 
concomi tant with functional motor recovery, even though 
a debate exists as to whether NPCs from the SVZ would 
transdifferentiate into nigral dopaminergic phenotypes or 
migrate into the striatum and then incorporate into host 
neurons (9). In addition to the molecular and cellular 
benefits of hMSCs, cell therapy with hMSCs has advan-
tages in clinical applications, such as ease of harvest from 
bone marrow, variety of administration roots, absence of 
immunological rejection, and absence of ethical problems. 
Importantly, our group recently reported that cell therapy 
with hMSCs in patients with multiple-system atrophy and 
ischemic stroke was feasible and safe (4,19,20). From a 
therapeutic perspective, the augmentative effects of hMSCs 
on endogenous adult neurogenesis along with the neuro-
protective properties in Parkinsonian disorders would be 
applicable clinically in future strategies for PD treatment. 
In summary, the present study demonstrated that hMSC 
administration significantly augmented neurogenesis in 
the SVZ of a PD animal model and increased differen-
tiation of NPCs into dopaminergic neurons in the SN. 
Our results suggest that the modulation of endogenous 
adult neurogenesis to repair the damaged PD brain using 
hMSCs would have a significant impact on future strate-
gies for PD treatment.
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